Cummins Inc
Change company Symbol lookup
Select an option...
CMI Cummins Inc
INVH Invitation Homes Inc
OII Oceaneering International Inc
SINO Sino-Global Shipping America Ltd
MLM Martin Marietta Materials Inc
KO Coca-Cola Co
VICI VICI Properties Inc
PLT Plantronics Inc
THG Hanover Insurance Group Inc
USB U.S. Bancorp
Go

Industrials : Machinery | Large Cap Value
Company profile

Cummins Inc. designs, manufactures, distributes and services diesel and natural gas engines and engine-related component products. The Company's segments include Engine, Distribution, Components and Power Systems. The Engine segment manufactures and markets a range of diesel and natural gas powered engines under the Cummins brand name, as well as certain customer brand names, for the heavy and medium-duty truck, bus, recreational vehicle (RV), light-duty automotive and agricultural markets. The Distribution segment consists of the product lines, which service and/or distribute a range of products and services, including parts, engines, power generation and service. The Components segment supplies products, including aftertreatment systems, turbochargers, filtration products and fuel systems for commercial diesel applications. The Power Systems segment consists of businesses, including Power generation, Industrial and Generator technologies.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$219.89
Day's Change
2.45 (1.13%)
Bid
--
Ask
--
B/A Size
--
Day's High
219.98
Day's Low
214.32
Volume
(Average)
Volume:
1,092,360

10-day average volume:
1,054,574
1,092,360

Abcentra Appoints Accomplished Drug Developer, Timothy Wright, to Board of Directors

3:20 pm ET August 26, 2020 (PR Newswire) Print

Abcentra LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for cardiovascular diseases, is pleased to announce Timothy Wright, M.D., General Partner at Time Bioventures, has joined the Company's Board of Directors. Wright is an accomplished rheumatologist and drug developer with an impressive track record. His leadership was instrumental in the development of several commercially successful therapeutics.

Wright joins Abcentra having held senior leadership roles in R&D at Pfizer, Novartis, California Institute for Biomedical Research (Calibr/Scripps Research), and Regulus Therapeutics. In these roles in Pharma and Biotech, he contributed to over 100 drug development programs, resulting in numerous marketed products including Lyrica(R), Ilaris(R), Cosentyx(R), and Entresto(R).

After completing his M.D., post-doctoral clinical, and research training at Johns Hopkins, Wright served as Chief of Rheumatology at the University of Pittsburgh. He has published more than 50 peer-reviewed publications, book chapters and reviews.

"As a significant stakeholder in Abcentra, Cedars-Sinai is delighted that the company has added yet another talented leader to the team," said Edward Prunchunas, Abcentra Board Member and Chief Financial Officer of Cedars-Sinai Health System in Los Angeles. "Abcentra stands to benefit tremendously from Dr. Wright's extensive drug development and medical background. We extend our warmest welcome to Dr. Wright and look forward to working with him."

"I am very excited to be a part Abcentra's team and to contribute my background and expertise to Abcentra's programs, which address serious unmet medical needs in cardiovascular disease," said Wright. "Orticumab, and Abcentra's other biologics in development, are uniquely suited to advance the standard of care in diseases with increased cardiometabolic risk. I look forward to working with the management team as we advance orticumab into clinical development within the next few months."

About Abcentra

Abcentra is a clinical-stage biopharmaceutical company developing new drugs for cardiovascular diseases. Our pipeline focuses on patient populations with high-risk of cardiometabolic complications that are exacerbated by chronic inflammation for which there are currently no suitable therapeutics, including patients with inflammatory diseases and patients with residual inflammation from lipoprotein(a). Our lead compound, orticumab, is a novel monoclonal antibody the blocks inflammation from oxidized low-density lipoprotein and is slated to begin a phase 2 study later this year.

www.abcentra.com

Media Contact:

Megan Humphreys

mhumphreys@conve.com

https://c212.net/c/img/favicon.png?sn=LA07763&sd=2020-08-26

View original content:http://www.prnewswire.com/news-releases/abcentra-appoints-accomplished-drug-developer-timothy-wright-to-board-of-directors-301119193.html

SOURCE Abcentra

https://rt.prnewswire.com/rt.gif?NewsItemId=LA07763&Transmission_Id=202008261520PR_NEWS_USPR_____LA07763&DateId=20200826

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.